drugset / Trial / NCT04054999
Methylene Blue vs Cyanokit for Intraoperative Vasoplegic Syndrome in Liver Transplant Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will evaluate if Hydroxocobalamin may be a new and possibly superior treatment for refractory vasoplegic syndrome during liver transplant surgery.
Timeline
- Start
- 2019-11-30
- Primary completion
- 2023-02-27
- Completion
- 2024-02-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hydroxocobalamin | Unknown | 5 g | Intravenous |
| Comparator | Methylene Blue | Diagnostic / imaging agent | 2 mg/kg | Intravenous |
Indications
No indication recorded.